English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.


Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Changsha IFS and Steven Harrington Join Hands to Introduce New Trends of Pop Culture in Changsha  
Aug 17, 2018 18:40 HKT/SGT
ABCC - the World-class Cryptocurrency Exchange - Announced an Airdrop of 150,000 USDT  
Aug 17, 2018 18:25 HKT/SGT
Spackman Entertainment Group's Frame Pictures Secures Four Major Camera Equipment Deals for Korean Film GIRL COPS And Three Upcoming Korean Dramas: THE GREATEST DIVORCE, THE BEAUTY INSIDE, HUNDRED MILLION STARS FALLING FROM THE SKY  
Aug 17, 2018 18:20 HKT/SGT
Trillium Selected as Plug and Play's Hottest Company  
Aug 17, 2018 14:00 HKT/SGT
FASHIONALLY Designers Set to Dazzle CENTRESTAGE 2018  
Aug 17, 2018 11:30 HKT/SGT
Managing Risk: Reputation events twice as costly for companies since rise of social media  
Aug 17, 2018 10:20 HKT/SGT
Meet The Team Behind AYANA's New Aqua Fleet  
Aug 17, 2018 09:50 HKT/SGT
Los Angeles to host 2018 US China Blockchain and Digital Currency Conference on August 22  
Aug 17, 2018 08:30 HKT/SGT
Global Master of Business Administration (MBA) Degree by University Of London Launches In Singapore  
Aug 16, 2018 20:45 HKT/SGT
Champion REIT Announces 2018 Interim Results  
Aug 16, 2018 18:45 HKT/SGT
More Press release >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: